Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers
详细信息 查看全文
- 作者：David M. Reinera ; David.reiner@bayer.com" class="auth_mail" title="E-mail the corresponding author ; Prakash Bhuyanb ; Prakash.Bhuyan@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Joseph J. Eidenc ; joseph.eiden@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; John Ginisb ; john.ginis@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Shannon Harrisc ; Shannon.Harris@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Kathrin U. Jansenc ; kathrin.jansen@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Qin Jiangb ; qin.jiang@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Thomas R. Jonesc ; thomas.r.jones@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Robert E. O&rsquo ; Neillc ; robert.oneill@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Laura J. Yorkd ; laura.york@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; John L. Perezb ; john.perez@pfizer.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：Neisseria meningitidis ; Serogroup B ; Vaccine ; Meningococcal disease ; Bivalent rLP2086 ; Laboratory worker
- 刊名：Vaccine
- 出版年：2016
- 出版时间：3 February 2016
- 年：2016
- 卷：34
- 期：6
- 页码：809-813
- 全文大小：514 K
文摘
- class="listitem" id="list_lis0005">
- class="label">•
Scientists handling Neisseria meningitidis are at increased risk for meningococcal disease.
- class="label">•
Bivalent rLP2086 vaccination should protect against N. meningitidis serogroup B.
- class="label">•
Vaccine immunogenicity, safety were tested in laboratory workers 24–62 years old.
- class="label">•
Vaccination elicited protective immune responses against 4 diverse MnB strains.
- class="label">•
These results support bivalent rLP2086 vaccination in this at-risk population.